- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Earnings at the firms can't compare to Goldman Sachs' performance.
The fund founded by a former Bears player hits the skids.
The hedge fund is accused of illegal short-selling.
Will BofA buy Barclays? Will Citi split? Where's de Molina?
Apollo Investment shares rise despite the loss of execs.
The bank boots a big settlement for the second time in two years.
It won't buy Ameritrade or E*Trade, the CEO says.
The biotech gets pounded just weeks after a timely stock sale.
But are the investors really getting their money's worth?
If regulations are so bad, why are stocks up?